Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Ava, Shamban"'
Publikováno v:
Aesthetic Surgery Journal.
Background VYC-12L is a hyaluronic acid filler to improve skin quality. A prospective study showed safety and effectiveness of VYC-12L for improving cheek skin smoothness and fine lines. Objectives To report participant-reported outcomes, subgroup an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef6b88d462165e8a471a84ce9623d06f
https://doi.org/10.1093/asj/sjad111
https://doi.org/10.1093/asj/sjad111
Autor:
Jeffrey S. Dover, Shannon D. Humphrey, Z. Paul Lorenc, Ava Shamban, Todd M. Gross, Roman G. Rubio, Domenico Vitarella
Publikováno v:
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 49(1)
Simultaneous treatment of moderate-to-severe upper facial lines is reflective of real-world clinical practice.To evaluate the efficacy and safety of daxibotulinumtoxinA-lanm for injection (DAXI) for simultaneous treatment of glabellar, forehead, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d29f9d850fa36138aa2e313f8d55d6
https://pubmed.ncbi.nlm.nih.gov/36533798
https://pubmed.ncbi.nlm.nih.gov/36533798
Publikováno v:
Journal of Cosmetic Dermatology. 20:569-576
Background Effective nonsurgical treatments for the aging face are widely accepted and utilized. Although changes in the aging neck, often patients to seek esthetic rejuvenation protocols are neither well defined nor well designed. Increasingly, pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25aa6787ecdcb4c1bb4a067d52d7644e
https://doi.org/10.1111/jocd.13877
https://doi.org/10.1111/jocd.13877
Autor:
Kian Karimi, Joel L. Cohen, Sarah Coquis-Knezek, Ava Shamban, Matthew H Meckfessel, Vanessa Lane, Corey S. Maas, Carolyn I. Jacob, Joel Schlessinger
Publikováno v:
Dermatologic Surgery
Supplemental Digital Content is Available in the Text.
BACKGROUND Real-world re-treatment intervals for botulinum toxins vary, but most subjects receive treatment less frequently than the manufacturer-recommended minimum intervals. In subjects r
BACKGROUND Real-world re-treatment intervals for botulinum toxins vary, but most subjects receive treatment less frequently than the manufacturer-recommended minimum intervals. In subjects r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62f3c3d3e061197ccbc77fdec47b0c87
https://doi.org/10.1097/dss.0000000000002846
https://doi.org/10.1097/dss.0000000000002846
Autor:
Jean D. Carruthers, Steve Fagien, John H. Joseph, Shannon D. Humphrey, Brian S. Biesman, Conor J. Gallagher, Yan Liu, Roman G. Rubio, Joel L. Cohen, Stephen Ho, Sue Ellen Cox, John Soderberg, Arthur Swift, Daniel Borsuk, Vasilios Papanastasiou, Ava Shamban, Soheil Simzar, Vince Bertucci, Brittany Waller, Charles Boyd, Molly Katz, Lauren Churchill, Stacy Smith, Cheryl Burgess, Karan Dhir, Zoe Draelos, Michael Draelos, Nathan Rosen, Channy Muhn, Ashish C. Bhatia, Shraddha Desai, Te-Shao Hsu, Christopher T. Kelly, Brandice M. Brazell, Jeanine Downie, Bruce Katz, Marianne Woody, Mary Lupo, Skylar Souyoul, Kavita Mariwalla, Joseph Eviatar, Wm. Philip Werschler, Scott Schade, Richard G. Glogau, Derek Jones, Jeanette M. Black, Naissan Wesley, Joely Kaufman-Janette, Joel Schlessinger, Jacqueline Hall, Shea Perillo, Jeffrey Dover, Laurel Morton, Nowell Solish, Gary Monheit, Heidi Essig, Steve Yoelin
Publikováno v:
Plastic and Reconstructive Surgery
Background: DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A formulation in clinical development. A phase 2 dose-ranging study identified an optimal dose and demonstrated efficacy with a median duration of 24 weeks. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af1e46ba09671d0d8a5957c8b1af5b15
https://doi.org/10.1097/prs.0000000000006327
https://doi.org/10.1097/prs.0000000000006327
Autor:
Ava Shamban, Suzanne Bruce, John H Joseph, Laura Eaton, Alayne Lehman, Steven R. Cohen, James M. Spencer, Ruth Tedaldi, Phillip Werschler, Valerie D. Callender, Pearl E. Grimes
Publikováno v:
Dermatologic Surgery. 45:1558-1566
This trial evaluated the effectiveness and safety of Bellafill for full-face acne scar treatment.In this open-label, nonrandomized, multicenter pilot study investigating the use of polymethylmethacrylate for full-face atrophic acne scar correction, 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5de3a03e66d232e781d509f07f10f04
https://doi.org/10.1097/dss.0000000000001863
https://doi.org/10.1097/dss.0000000000001863
Autor:
Greg J Goodman, Ava Shamban, Peter Callan, Izolda Heydenrych, Cara B McDonald, Stefania Roberts, Steven Liew, Krishan Mohan Kapoor, Philip S Bekhor, Tatjana Pavicic, Alice Rudd, Ashish C. Bhatia, Shobhan Manoharan, Mark R. Magnusson, Sean Arendse, Michael Molton, Michael Clague, Sarah Hart, Katy Wallace, David E Kosenko, Peter Hsien-Li Peng, Niamh Corduff
Publikováno v:
Aesthetic Surgery Journal
Background Hyaluronic acid fillers have a satisfactory safety profile. However, adverse reactions do occur, and rarely intravascular injection may lead to blindness. Currently there is no internationally recognized consensus on the prevention or mana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c93fd173242733a53ac56e499e041484
https://doi.org/10.1093/asj/sjz312
https://doi.org/10.1093/asj/sjz312
Publikováno v:
Dermatologic Surgery
Supplemental Digital Content is Available in the Text.
BACKGROUND PrabotulinumtoxinA is a 900-kDa botulinum toxin Type A produced by Clostridium botulinum. OBJECTIVE To investigate the efficacy and safety of prabotulinumtoxinA for the treatment
BACKGROUND PrabotulinumtoxinA is a 900-kDa botulinum toxin Type A produced by Clostridium botulinum. OBJECTIVE To investigate the efficacy and safety of prabotulinumtoxinA for the treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57e7cc0e488684688f1a16585e32fbb9
https://doi.org/10.1097/dss.0000000000001903
https://doi.org/10.1097/dss.0000000000001903
Autor:
Ava Shamban
Publikováno v:
Journal of Cosmetic Dermatology. 18:692-699
Signature FeatureTM (SF) is a universal, yet highly personalized treatment approach to aesthetic facial enhancement that applies to all patients, independent of age, gender, or ethnicity. Its philosophical basis maintains that a patient's beauty is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f7dc27ed09326c79e3c2f82408fabd1
https://doi.org/10.1111/jocd.12944
https://doi.org/10.1111/jocd.12944
Publikováno v:
Toxicon. 214:S11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8937cf6e2a139de2573d13a85cfd4686
https://doi.org/10.1016/j.toxicon.2021.11.034
https://doi.org/10.1016/j.toxicon.2021.11.034